Breaking News
Investing Pro 0
Last Call for Cyber Monday! Save Now on Claim 60% OFF

Bristol Myers Squibb slumps as FDA convenes advisory panel for drug application

Published Nov 20, 2023 09:30AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
BMY
-0.39%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
VTVT
+55.87%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Investing.com -- Shares in Bristol-Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) fell in early trading on Monday after the pharma giant and its partner announced that U.S. health regulators will not meet a deadline next month to potentially approve earlier use of a blood cancer therapy.

Bristol Myers Squibb developed the drug, known as Abecma, with 2seventy bio as a treatment for adult patients suffering from multiple myeloma, a type of blood cancer that arises from plasma cells in bone marrow. The U.S. Food and Drug Administration (FDA) previously approved use of the treatment if four or more prior therapies did not lead to improvement in patients.

But the FDA told the companies that it will not be able to provide a decision on an application to introduce Abecma for earlier lines of treatment before its target date of Dec. 16, saying it will seek the advice of an independent committee of experts. The FDA added that it has not yet confirmed a date for a meeting of the panel, known as the Oncologic Drugs Advisory Committee (ODAC).

The application was based on the outcome of a late-stage trial that demonstrated Abecma "significantly" reduced the risk of disease progression or death versus "standard regimens" in patients with relapsed or refractory multiple myeloma.

Bristol Myers Squibb and 2seventy bio said in a statement that they "look forward to continuing discussions with the FDA and participating in the ODAC meeting."

Bristol Myers Squibb slumps as FDA convenes advisory panel for drug application
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email